1 / 12

Therapeutic Drug Monitoring

Therapeutic Drug Monitoring. Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action Has been established on the principle that the concentration correlates better than the dose with the drug effect Is important when

felix
Télécharger la présentation

Therapeutic Drug Monitoring

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Therapeutic Drug Monitoring • Relates concentrations of drug in blood to response • Blood concentrations surrogate for the concentration at the site of action • Has been established on the principle that the concentration correlates better than the dose with the drug effect • Is important when • the dose cannot be titrated against response eg INR, cholesterol • the drug is being used to prevent infrequent occurrences - eg epilepsy

  2. Conditions that must be met • Blood concentrations can be accurately reliably and economically measured • There is sufficient inter-individual variation in drug handling to warrant individualisation of dose • There is a clear relationship between concentration and beneficial and/or adverse effects, particularly if there is a narrow therapeutic index • The effects are due to the parent drug and not its metabolites

  3. Purpose of TDM • To confirm ‘effective’ concentrations • To investigate unexpected lack of efficacy • To check compliance • To avoid or anticipate toxic concentrations • Before increasing to unusually large doses • Limited role in toxicology - drug screen

  4. Pharmacokinetic Considerations • Is the aim to provide constant concentrations? - eg anticonvulsants • Is the aim to achieve transient high concentrations without toxicity? - eg gentamicin • Are drug concentrations likely to vary greatly between individuals on the same dose? - eg phenytoin • Remember it takes around 5 half-lives to reach steady state

  5. Practical considerations • Can the lab actually measure the drug? • What sample is needed? • What is the right timing? • Is there an accepted ‘therapeutic range’ • MEC - threshold concentration above which efficacy is expected in most patients with the disorder • MTC - upper concentration above which the rate and severity of adverse effects become unacceptable

  6. Methodological Difficulties in establishing ‘Therapeutic Range’ • Good data relating concentration to effect are seldom available • Ideally it would require trials where participants were randomised to different plasma concentrations with follow-up and accurate and unbiased measurement of the outcomes • See diagram of therapeutic range

  7. TDM - examples • Lithium - used for bipolar disorder • Toxic - neurological, cardiac, renal • Narrow therapeutic range: • 0.8 - 1.2 mmol/L acutely • 0.5 - 0.75 mmol/L for maintenance • Chronic concentrations of 3.0 are potentially lethal • Renal clearance of Li can be affected by diuretics and NSAIDs

  8. Anticonvulsants • Variable dose dependant kinetics • Most metabolised through cytochrome P450 system • Concentration-related CNS toxicity can be partly avoided by TDM • However severe skin rashes, liver and marrow toxicity cannot be predicted or avoided • With phenytoin small dose increases can produce disproportionate rises in blood levels and toxicity • Sometimes free (unbound) concentrations need to be measured - eg hypoalbuminaemia, pregnancy

  9. Digoxin • Has variable bioavailability • Has variable clearance (by kidney) - remember the elderly • Drug interactions are fairly common • Relationship between concentration and effect is not constant - concentrations soon after dosing are difficult to interpret. Range is approx 1 to 2 nmol/L • Patients may become more ‘sensitive’ to a given concentration - eg hypokalalaemia, hypothyroidism • In atrial fibrillation titrate against the ventricular rate • Concentrations should be measure at least 6-8 hours after the last dose

  10. Cyclosporin • Used as immunosuppressant in transplant rejection • Low therapeutic index and toxicity (kidney) is severe • Interactions are common - eg calcium channel antagonists • Plasma range 50-300 mg/L

  11. Theophylline • Declining use in asthma • Very narrow therapeutic index: 55 - 110 umol/L (should be lower) • At the high end toxicity is common • Toxicity is severe - GI, neuro, cardiac • Interactions are common - erythromycin, cyclosporin, cimetidine, smoking

  12. Gentamicin • Practice is changing - trend to once/daily dosing • Toxicity relates to trough concentrations, particularly with prolonged therapy • Desirable range: • peak 6 - 10 mg/L • trough 1-2 mg/L

More Related